临床精神医学杂志
臨床精神醫學雜誌
림상정신의학잡지
JOURNAL OF CLINICAL PSYCHOLOGICAL MEDICINE
2015年
3期
197-199
,共3页
储文革%陈燕%赵宜生%赵兵%许志平%邱睿%梁涛%程利民%王卫民
儲文革%陳燕%趙宜生%趙兵%許誌平%邱睿%樑濤%程利民%王衛民
저문혁%진연%조의생%조병%허지평%구예%량도%정이민%왕위민
精神分裂症%抗精神病药%认知功能
精神分裂癥%抗精神病藥%認知功能
정신분렬증%항정신병약%인지공능
schizophrenia%antipsychotic drugs%cognitive function
目的:比较利培酮、奥氮平、奎硫平、阿立哌唑、齐拉西酮、氨磺必利6种抗精神病药对急性期首发精神分裂症患者认知功能的影响。方法:120例精神分裂症首发患者分为6个药物组,每组各20例,分别给予6种抗精神病药治疗,观察12周。采用阳性和阴性症状量表( PANSS)、韦氏成人智力测验( WAIS-RC)、威斯康星卡片分类测验( WCST)、临床记忆量表( CMS)在治疗前后评估疗效及认知功能。结果:与治疗前相比,各药物组PANSS阳性症状、阴性症状及总分在治疗后各时点均明显下降(P<0.05或P<0.01);WAIS-RC、CMS、WCST评分均明显改善(P<0.05或P<0.001);各组间比较,差异无统计学意义。相关分析显示,总智商差值与 PANSS总分及阴性症状差值呈正相关性( r=0.559, r=0.755;P<0.01或P<0.001),与阳性症状差值无相关( r=0.148,P>0.05)。结论:6种新型抗精神病药均能改善首发精神分裂症患者的认知功能。
目的:比較利培酮、奧氮平、奎硫平、阿立哌唑、齊拉西酮、氨磺必利6種抗精神病藥對急性期首髮精神分裂癥患者認知功能的影響。方法:120例精神分裂癥首髮患者分為6箇藥物組,每組各20例,分彆給予6種抗精神病藥治療,觀察12週。採用暘性和陰性癥狀量錶( PANSS)、韋氏成人智力測驗( WAIS-RC)、威斯康星卡片分類測驗( WCST)、臨床記憶量錶( CMS)在治療前後評估療效及認知功能。結果:與治療前相比,各藥物組PANSS暘性癥狀、陰性癥狀及總分在治療後各時點均明顯下降(P<0.05或P<0.01);WAIS-RC、CMS、WCST評分均明顯改善(P<0.05或P<0.001);各組間比較,差異無統計學意義。相關分析顯示,總智商差值與 PANSS總分及陰性癥狀差值呈正相關性( r=0.559, r=0.755;P<0.01或P<0.001),與暘性癥狀差值無相關( r=0.148,P>0.05)。結論:6種新型抗精神病藥均能改善首髮精神分裂癥患者的認知功能。
목적:비교리배동、오담평、규류평、아립고서、제랍서동、안광필리6충항정신병약대급성기수발정신분렬증환자인지공능적영향。방법:120례정신분렬증수발환자분위6개약물조,매조각20례,분별급여6충항정신병약치료,관찰12주。채용양성화음성증상량표( PANSS)、위씨성인지력측험( WAIS-RC)、위사강성잡편분류측험( WCST)、림상기억량표( CMS)재치료전후평고료효급인지공능。결과:여치료전상비,각약물조PANSS양성증상、음성증상급총분재치료후각시점균명현하강(P<0.05혹P<0.01);WAIS-RC、CMS、WCST평분균명현개선(P<0.05혹P<0.001);각조간비교,차이무통계학의의。상관분석현시,총지상차치여 PANSS총분급음성증상차치정정상관성( r=0.559, r=0.755;P<0.01혹P<0.001),여양성증상차치무상관( r=0.148,P>0.05)。결론:6충신형항정신병약균능개선수발정신분렬증환자적인지공능。
Objective:To make a comparison of the effects of the acute treatment with six kinds of antip-sychotic drugs,risperidone,olanzapine,quetiapine,aripiprazole,ziprasidone and amisulprid,on the cognitive function in patients with first-episode schizophrenia. Method:One hundred and twenty schizophrenic patients were divided into 6 groups,each group made up of 20 cases. Cases from each group receive medical treatment with one of the six antipsychotic drugs respectively and undergo the medical observation for 12 weeks. Positive and negative syndrome scale( PANSS),Wechsler adult intelligence scale-revised-China( WAIS-RC),Wisconsin card sort test(WCST)and clinical memory scale(CMS)were applied to make an assessment of the patients′therapeutic effectiveness and the improvement of cognitive function before and after the treatment. Resuits:After the treatment with different kinds of antipsychotic drugs,the PANSS positive,negative and total treatment scale scores of schizophrenia patients on each group at all time points declined obviously( P < 0. 05 or P<0. 01). Different index scores of WAIS-RC,CMS and WCST were clearly improved( P < 0. 05 or P<0. 001). Comparison between groups showed no statistical significance. Pearson correlation indicated that full intelligence quotient difference had a positive correlation with PANSS total score and negative syndrome difference(r=0. 559,r=0. 755;P<0. 01 or P<0. 001),while no correlation with positive syndrome differ-ence(r=0. 148,P>0. 05). Conciusion:The six kinds of newly-developed antipsychotic drugs can improve the cognitive function of first-episode schizophrenia patients.